Alkermes' Commercial Business Appears Strong Enough to Fund Orexin Pipeline, RBC Capital Markets Says

MT Newswires Live11-05

Alkermes' (ALKS) commercial business appears capable of funding increasing investment in the orexin pipeline following a Q3 beat, RBC Capital Markets said in a note Tuesday.

The company reported Q3 revenue of $480.1 million, up from $394.2 million a year earlier and above consensus of about $464 million. RBC said Alkermes' portfolio posted a solid topline beat and 2026 revenue could exceed the $1.84 billion higher end of the company's guidance.

Alkermes' orexin pipeline presents substantial upside potential, the brokerage said, noting the FDA-approved Lumryz and upcoming trial data of alixorexton in idiopathic hypersomnia. RBC estimates Lumryz sales growing to $411 million in 2027 and $3.3 billion in alixorexton sales by 2035.

RBC has an outperform rating on Alkermes, with a higher price target of $57 from $56.

Alkermes shares were down more than 1% in Wednesday trading.

Price: 45.20, Change: -0.49, Percent Change: -1.07

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment